Anti‐epidermal growth factor receptor therapy for glioblastoma in adults
Background Glioblastoma is an uncommon but highly aggressive type of brain tumour.
Significant gains have been achieved in the molecular understanding and the pathogenesis …
Significant gains have been achieved in the molecular understanding and the pathogenesis …
Leptomeningeal melanoma-A case series in the era of modern systemic therapy.
M Arasaratnam, A Hong, B Shivalingam… - Pigment Cell & …, 2017 - europepmc.org
Leptomeningeal melanoma-A case series in the era of modern systemic therapy. - Abstract -
Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu About Tools …
Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu About Tools …
Inter-and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer
M Arasaratnam, M Crumbaker, A Bhatnagar… - Cancer Chemotherapy …, 2019 - Springer
Purpose This study examined the inter-and intra-patient variability in pharmacokinetics of AA
and its metabolites abiraterone and Δ (4)-abiraterone (D4A), and potential contributing …
and its metabolites abiraterone and Δ (4)-abiraterone (D4A), and potential contributing …
Bioanalytical evaluation of dried plasma spots for monitoring of abiraterone and∆(4)-abiraterone from cancer patients
A Bhatnagar, MJ McKay, M Thaysen-Andersen… - … of Chromatography B, 2019 - Elsevier
Abiraterone acetate is an approved prodrug administered orally in a fixed dose format for the
treatment of metastatic castration-resistant prostate cancer (mCRPC). In vivo, the prodrug is …
treatment of metastatic castration-resistant prostate cancer (mCRPC). In vivo, the prodrug is …
Outcomes of retroperitoneal lymph node dissection for testicular cancer by a high volume surgeon from Australia: a case for centralisation
ISC Williams, J Lahoud, H Gurney… - ANZ Journal of …, 2022 - Wiley Online Library
Background There are few studies examining retroperitoneal lymph node dissection
(RPLND) for testicular cancer in Australia. This study examines the perioperative outcomes …
(RPLND) for testicular cancer in Australia. This study examines the perioperative outcomes …
Nivolumab in the treatment of advanced renal cell carcinoma
M Arasaratnam, H Gurney - Future Oncology, 2018 - Future Medicine
Renal cell carcinoma (RCC) has typically been considered an immunogenic malignancy
with responses seen to IL-2 and IFN-α. Response rates, however, were low and at the cost …
with responses seen to IL-2 and IFN-α. Response rates, however, were low and at the cost …
Drug reaction with eosinophilia and systemic symptoms in metastatic basal cell carcinoma treated with vismodegib.
CL Thomas, M Arasaratnam, G Carlos… - Australasian …, 2017 - search.ebscohost.com
The article presents a case study of a 68-year-old man with metastatic basal cell carcinoma
(BCC) with symptoms and signs consistent with a drug reaction of eosinophilia and systemic …
(BCC) with symptoms and signs consistent with a drug reaction of eosinophilia and systemic …
Evaluating bioanalytical capabilities of paper spray ionization for abiraterone drug quantification in patient plasma
A Bhatnagar, MJ McKay, M Arasaratnam… - Journal of mass …, 2020 - Wiley Online Library
Paper spray ionization (PSI) is a direct, fast, and low‐cost ambient ionization technique
which may have clinical utility for qualitative and quantitative analysis of therapeutic drugs …
which may have clinical utility for qualitative and quantitative analysis of therapeutic drugs …
Patterns of care and outcomes of men with germ cell tumors in a high‐volume Australian center
M Arasaratnam, B Balakrishnar… - Asia‐Pacific Journal …, 2022 - Wiley Online Library
Aim To evaluate disease presentation, treatment practices, and outcomes of patients with
germ cell tumor (GCT) treated in a high‐volume cancer center in Australia. Methods This is a …
germ cell tumor (GCT) treated in a high‐volume cancer center in Australia. Methods This is a …
Continuing cabazitaxel beyond 10 cycles for metastatic castrate-resistant prostate cancer: is there a benefit?
Aim Cabazitaxel prolongs survival in patients with metastatic castration-resistant prostate
cancer in the postdocetaxel setting. We investigate the benefit of continuing cabazitaxel …
cancer in the postdocetaxel setting. We investigate the benefit of continuing cabazitaxel …